NCT03777813 - Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions

Esophagus CancerUnresectable Malignant Neoplasm

Interventions

DRUG

Durvalumab

Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions

COMBINATION_PRODUCT

IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)

Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)

Trial Locations (7)

31059

Iuct, Clcc Unicancer, Toulouse

33604

Hôpital Haut-Lévêque, Pessac

75010

Hôpital Saint Louis, APHP, Paris

Unknown

Centre Oscar Lambret, CLCC UNICANCER, Lille

Centre Hospitalier Universitaire, Poitiers

Centre Paul Strauss, CLCC UNICANCER, Strasbourg

CHU Rangueil Larrey, Toulouse

All Listed Sponsors

lead

UNICANCER

OTHER